Literature DB >> 34662221

A Genome-Edited ERα-HiBiT Fusion Reporter Cell Line for the Identification of ERα Modulators Via High-Throughput Screening and CETSA.

Hunter G Larson1, Alexey V Zakharov1, Sukumar Sarkar2, Shyh-Ming Yang1, Ganesha Rai1, James M Larner2, Anton Simeonov1, Natalia J Martinez1.   

Abstract

The estrogen receptor α (ERα) is a target of intense pharmacological intervention and toxicological biomonitoring. Current methods to directly quantify cellular levels of ERα involve antibody-based assays, which are labor-intensive and of limited throughput. In this study, we generated a post-translational reporter cell line, referred to as MCF7-ERα-HiBiT, by fusing a small pro-luminescent nanoluciferase (NLuc) tag (HiBiT) to the C-terminus of endogenous ERα in MCF7 cells. The tag allows the luminescent detection and quantification of endogenous ERα protein by addition of the complementary NLuc enzyme fragment. This MCF7-ERα-HiBiT cell line was optimized for quantitative high-throughput screening (qHTS) to identify compounds that reduce ERα levels. In addition, the same cell line was optimized for a qHTS cellular thermal shift assay to identify compounds that bind and thermally stabilize ERα. Here, we interrogated the MCF7-ERα-HiBiT assay against the NCATS Pharmacological Collection (NPC) of 2,678 approved drugs and identified compounds that potently reduce and thermally stabilize ERα. Our novel post-translational reporter cell line provides a unique opportunity for profiling large pharmacological and toxicological compound libraries for their effect on ERα levels as well as for assessing direct compound binding to the receptor, thus facilitating mechanistic studies by which compounds exert their biological effects on ERα.

Entities:  

Keywords:  CETSA; ERα; HiBiT; qHTS

Mesh:

Substances:

Year:  2021        PMID: 34662221      PMCID: PMC8713567          DOI: 10.1089/adt.2021.059

Source DB:  PubMed          Journal:  Assay Drug Dev Technol        ISSN: 1540-658X            Impact factor:   1.738


  34 in total

1.  The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer.

Authors:  James D Joseph; Beatrice Darimont; Wei Zhou; Alfonso Arrazate; Amy Young; Ellen Ingalla; Kimberly Walter; Robert A Blake; Jim Nonomiya; Zhengyu Guan; Lorna Kategaya; Steven P Govek; Andiliy G Lai; Mehmet Kahraman; Dan Brigham; John Sensintaffar; Nhin Lu; Gang Shao; Jing Qian; Kate Grillot; Michael Moon; Rene Prudente; Eric Bischoff; Kyoung-Jin Lee; Celine Bonnefous; Karensa L Douglas; Jackaline D Julien; Johnny Y Nagasawa; Anna Aparicio; Josh Kaufman; Benjamin Haley; Jennifer M Giltnane; Ingrid E Wertz; Mark R Lackner; Michelle A Nannini; Deepak Sampath; Luis Schwarz; Henry Charles Manning; Mohammed Noor Tantawy; Carlos L Arteaga; Richard A Heyman; Peter J Rix; Lori Friedman; Nicholas D Smith; Ciara Metcalfe; Jeffrey H Hager
Journal:  Elife       Date:  2016-07-13       Impact factor: 8.140

2.  The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators.

Authors:  A L Wijayaratne; D P McDonnell
Journal:  J Biol Chem       Date:  2001-07-25       Impact factor: 5.157

3.  High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.

Authors:  Travis B Kinder; Patricia K Dranchak; James Inglese
Journal:  ACS Chem Biol       Date:  2020-06-10       Impact factor: 5.100

Review 4.  Environmental causes of cancer: endocrine disruptors as carcinogens.

Authors:  Ana M Soto; Carlos Sonnenschein
Journal:  Nat Rev Endocrinol       Date:  2010-05-25       Impact factor: 43.330

5.  The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics.

Authors:  Ruili Huang; Noel Southall; Yuhong Wang; Adam Yasgar; Paul Shinn; Ajit Jadhav; Dac-Trung Nguyen; Christopher P Austin
Journal:  Sci Transl Med       Date:  2011-04-27       Impact factor: 17.956

6.  Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.

Authors:  Chris De Savi; Robert H Bradbury; Alfred A Rabow; Richard A Norman; Camila de Almeida; David M Andrews; Peter Ballard; David Buttar; Rowena J Callis; Gordon S Currie; Jon O Curwen; Chris D Davies; Craig S Donald; Lyman J L Feron; Helen Gingell; Steven C Glossop; Barry R Hayter; Syeed Hussain; Galith Karoutchi; Scott G Lamont; Philip MacFaul; Thomas A Moss; Stuart E Pearson; Michael Tonge; Graeme E Walker; Hazel M Weir; Zena Wilson
Journal:  J Med Chem       Date:  2015-10-07       Impact factor: 7.446

7.  The dynamic structure of the estrogen receptor.

Authors:  Raj Kumar; Mikhail N Zakharov; Shagufta H Khan; Rika Miki; Hyeran Jang; Gianluca Toraldo; Rajan Singh; Shalender Bhasin; Ravi Jasuja
Journal:  J Amino Acids       Date:  2011-07-26

8.  Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.

Authors:  G L Powers; S J Ellison-Zelski; A J Casa; A V Lee; E T Alarid
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

9.  A widely-applicable high-throughput cellular thermal shift assay (CETSA) using split Nano Luciferase.

Authors:  Natalia J Martinez; Rosita R Asawa; Matthew G Cyr; Alexey Zakharov; Daniel J Urban; Jacob S Roth; Eric Wallgren; Carleen Klumpp-Thomas; Nathan P Coussens; Ganesha Rai; Shyh-Ming Yang; Matthew D Hall; Juan J Marugan; Anton Simeonov; Mark J Henderson
Journal:  Sci Rep       Date:  2018-06-21       Impact factor: 4.379

10.  Pocket similarity identifies selective estrogen receptor modulators as microtubule modulators at the taxane site.

Authors:  Yu-Chen Lo; Olga Cormier; Tianyun Liu; Kendall W Nettles; John A Katzenellenbogen; Tim Stearns; Russ B Altman
Journal:  Nat Commun       Date:  2019-03-04       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.